New triple-drug attack shows promise for hard-to-treat ovarian cancer
NCT ID NCT07286240
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of drugs for people whose ovarian cancer has returned after standard treatment. The drugs include a dual-target immunotherapy (QL1706), chemotherapy, and an oral anti-angiogenic agent (anlotinib). The goal is to see if this combo can shrink tumors or slow cancer growth. About 40 adults with recurrent ovarian cancer will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lipai Chen
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches
- New targeted therapy shows promise for Tough-to-Treat ovarian cancer
- Engineered immune cells target Hard-to-Treat ovarian cancer
- New combo therapy aims to control ovarian cancer and reduce painful fluid buildup
- New antibody combo shows promise for tough ovarian cancer